Joana Carvalho, PhD, managing science editor —

Injection of mesenchymal stromal cells (MSCs) — cells that can be isolated from several tissues and may grow into different cell types when cultured in a lab dish — may prevent localized skin blistering sometimes seen in recessive dystrophic epidermolysis bullosa (RDEB), a study says. Results from the study,…

With its lead therapy candidate AGLE-103 set to begin clinical testing in the coming months, Aegle Therapeutics is being honored with a Partners in Progress Award by the Dystrophic Epidermolysis Bullosa Research Association of America (Debra of America). Aegle is among three companies being recognized for its efforts to…

KB103, Krystal Biotech‘s investigational topical gene therapy for treating dystrophic epidermolysis bullosa (DEB), continues to show promise in the treatment of skin wounds and has received the designation of regenerative medicine advanced therapy (RMAT) from the U.S. Food and Drug Administration (FDA). DEB is a…

The first patient with epidermolysis bullosa has received treatment with RegeneRx Biopharmaceuticals‘ investigational therapy RGN-137 in a Phase 2 clinical trial in the U.S., the company announced. RGN-137 is a gel formulation medication intended to accelerate wound healing when applied directly onto skin lesions. It is based on…

King’s College London researchers created a new type of dressing glove for those with epidermolysis bullosa (EB), based on patients’ feedback. The glove was designed to adapt to patients’ hands, keeping fingers separated, facilitating wound dressing and improving their quality of life. The findings of the study, “Iterative codesign and…